Phase 1
N=72
A Study of LY3502970 in Healthy Overweight and Obese Participants
Healthy · Obese
Bottom Line
View on ClinicalTrials.gov: NCT05313802 ↗Enrolled (actual)
72
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 20; 21; 16 participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 1
- Interventions
- LY3502970 (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Eli Lilly and Company
- Primary completion
- Sep 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration |
20; 21; 16 | — |
| SECONDARY Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration (AUC[0-tlast]) of LY3502970 on Day 1 |
117; 66.1; 66.9 | — |
| SECONDARY PK: Maximum Observed Concentration (Cmax) of LY3502970 on Day 1 |
8.40; 4.97; 5.00 | — |
| SECONDARY PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 on Day 1 |
7.03; 6.00; 6.00 | — |
| SECONDARY PK: AUC[0-tlast] of LY3502970 on Day 28 |
275; 277; 314 | — |
| SECONDARY PK: Cmax of LY3502970 on Day 28 |
18.4; 18.4; 21.2 | — |
| SECONDARY PK: Tmax of LY3502970 on Day 28 |
6.00; 6.00; 6.00 | — |
| SECONDARY Pharmacodynamics (PD): Change From Baseline in Body Weight |
-4.2; -5.5; -3.6 | — |
Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3502970 in healthy overweight and obese participants. The blood tests will be conducted to measure how much LY3502970 is in the bloodstream and how the body handles and eliminates LY3502970 in these participants. The study will last up to 42 days excluding the screening period.
Eligibility Criteria
Inclusion Criteria
- Participants with stable body weight for at least one month prior to randomization.
- Participants with body mass index (BMI) of greater than or equal to (≥) 27.0 kilograms per meter squared (kg/m²)
- Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential
Exclusion Criteria
- Have known allergies to LY3502970 or other glucagon-like peptide-1 Receptor Agonists (GLP-1 RA) analogs
- Significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders
- Have any type of diabetes with hemoglobin A1c (HbA1c) ≥6.5 %
Data sourced from ClinicalTrials.gov (NCT05313802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.